Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Pharma Industry News Thryv Therapeutics secures FDA IND clearance to launch first potential drug for Long QT syndrome Thryv Therapeutics gains FDA IND clearance for THRV-1268 in Long QT Syndrome, aiming to pioneer the first disease-modifying therapy for this rare disorder. bySoujanya RaviSeptember 18, 2025